Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Pharmacokinetics of Mezlocillin in Patients with Kidney Impairment: Special Reference to Hemodialysis and Dosage Adjustments in Relation to Renal Function

Pharmacokinetics of Mezlocillin in Patients with Kidney Impairment: Special Reference to... The pharmacokinetics of Mezlocillin were determined after the intramuscular injection of a single 1-gram dose in 10 subjects with normal renal function, in 10 patients with stabilized renal impairment and in 5 patients with end-stage renal disease submitted to repeated hemodialysis. In normal subjects, biological half-life, T<sub>b </sub>½„ was equal to 0.9 h; total clearance (C<sub>t</sub>) to 449 ml/min/1.73 m<sup>2</sup>; renal clearance (C<sub>r</sub>) to 263 ml/min/1.73 m<sup>2</sup>.72.2% of the administered dose was excreted in the urine within 12 h. In patients with renal insufficiency and in patients undergoing long-term hemodialysis, the serum concentration decrease was markedly slower. During a 6-hour dialysis session, 62% of the Mezlocillin present in the central compartment at the start of hemodialysis was removed. In the 25 subjects under study, a significant correlation was found between the values of K<sub>e</sub> and those of creatinine clearance, C<sub>cr</sub> (K<sub>e</sub>=0.1973+ 0.0046 C<sub>cr</sub>). This relation was used to calculate the loading doses, the maintenance doses and the dosage intervals adjusted to the degree of renal impairment, allowing assessment of useful dosage recommendations. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Chemotherapy Karger

Pharmacokinetics of Mezlocillin in Patients with Kidney Impairment: Special Reference to Hemodialysis and Dosage Adjustments in Relation to Renal Function

Brogard, J.M.; Comte, F.; Spach, M.O.; Lavillaureix, J.
Chemotherapy , Volume 28 (5): 9 – Jan 1, 1982
Download PDF
9 pages

Loading next page...
 
/lp/karger/pharmacokinetics-of-mezlocillin-in-patients-with-kidney-impairment-NGl8N7YU2T

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 1982 S. Karger AG, Basel
ISSN
0009-3157
eISSN
1421-9794
DOI
10.1159/000238098
Publisher site
See Article on Publisher Site

Abstract

The pharmacokinetics of Mezlocillin were determined after the intramuscular injection of a single 1-gram dose in 10 subjects with normal renal function, in 10 patients with stabilized renal impairment and in 5 patients with end-stage renal disease submitted to repeated hemodialysis. In normal subjects, biological half-life, T<sub>b </sub>½„ was equal to 0.9 h; total clearance (C<sub>t</sub>) to 449 ml/min/1.73 m<sup>2</sup>; renal clearance (C<sub>r</sub>) to 263 ml/min/1.73 m<sup>2</sup>.72.2% of the administered dose was excreted in the urine within 12 h. In patients with renal insufficiency and in patients undergoing long-term hemodialysis, the serum concentration decrease was markedly slower. During a 6-hour dialysis session, 62% of the Mezlocillin present in the central compartment at the start of hemodialysis was removed. In the 25 subjects under study, a significant correlation was found between the values of K<sub>e</sub> and those of creatinine clearance, C<sub>cr</sub> (K<sub>e</sub>=0.1973+ 0.0046 C<sub>cr</sub>). This relation was used to calculate the loading doses, the maintenance doses and the dosage intervals adjusted to the degree of renal impairment, allowing assessment of useful dosage recommendations.

Journal

Chemotherapy – Karger

Published: Jan 1, 1982

Keywords: Dosage adjustments; Pharmacokinetics; Mezlocillin; Normal subjects; Renal impairment; Hemodialysis

There are no references for this article.